Harrow (HROW) Liabilities and Shareholders Equity (2010 - 2026)
Harrow (HROW) posted quarterly Liabilities and Shareholders Equity of $419.5 million for Q1 2026, up 15.21% year-over-year from $364.2 million in Q1 2025, and up 5.02% quarter-over-quarter from $399.5 million in Q4 2025.
Harrow (HROW) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Harrow's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $419.5 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 15.21% year-over-year to $419.5 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 8.21% YoY), while the FY2025 annual figure was $399.5 million, up 2.7% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $419.5 million, up from $399.5 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $419.5 million in Q1 2026, with the low at $97.6 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $306.6 million (2024), against an average of $278.0 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity retreated 8.32% in 2022, then surged 188.98% in 2023.
- Harrow's Liabilities and Shareholders Equity stood at $157.4 million in 2022, then surged by 98.35% to $312.2 million in 2023, then increased by 24.6% to $389.0 million in 2024, then grew by 2.7% to $399.5 million in 2025, then grew by 5.02% to $419.5 million in 2026.
- Business Quant data shows HROW's Liabilities and Shareholders Equity at $419.5 million in Q1 2026, $399.5 million in Q4 2025, and $363.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Harrow | 1.55 Bn | 1.47 Bn | 50.36 Mn | 416.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 416.82 Mn |
| Mar 31, 2026 | 419.54 Mn |
| Dec 31, 2025 | 399.48 Mn |
| Sep 30, 2025 | 363.07 Mn |
| Jun 30, 2025 | 345.03 Mn |
| Mar 31, 2025 | 364.16 Mn |
| Dec 31, 2024 | 388.97 Mn |
| Sep 30, 2024 | 351.54 Mn |
| Jun 30, 2024 | 306.63 Mn |
| Mar 31, 2024 | 295.54 Mn |
| Dec 31, 2023 | 312.16 Mn |
| Sep 30, 2023 | 286.07 Mn |
| Jun 30, 2023 | 223.99 Mn |
| Mar 31, 2023 | 217.50 Mn |
| Dec 31, 2022 | 157.38 Mn |
| Sep 30, 2022 | 98.99 Mn |
| Jun 30, 2022 | 98.06 Mn |
| Mar 31, 2022 | 97.60 Mn |
| Dec 31, 2021 | 98.33 Mn |
| Sep 30, 2021 | 102.80 Mn |